Department of Respiratory and Critical Care, Chinese PLA General Hospital, Beijing, China.
Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing, China.
Comput Biol Med. 2022 Dec;151(Pt A):106213. doi: 10.1016/j.compbiomed.2022.106213. Epub 2022 Oct 23.
To explore the expression of hyaluronan mediated motility receptor (HMMR) in lung adenocarcinoma (LUAD) and its relationship with clinicopathological features and tumor-infiltrating is not clear.
The expression of HMMR in Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA)-LUAD. TCGA was employed to examine the relationship between the clinicopathological characteristics and HMMR expression and the LUAD patients' prognosis. Tumor Immune Estimation Resource (TIMER)database was employed to analyze the relationship between immune infiltration and HMMR. Gene Set Enrichment Analysis was explored through gene enrichment. Gene Expression Omnibus (GEO) data and our hospital data were utilized to confirm the findings.
The expression level of HMMR in lung adenocarcinoma tissue and cells was greater than that in the normal group, which was linked to clinical stage, smoking history, and recurrence, and could increase the progression or recurrence of LUAD. Patients in the pathological grade had a significant expression of HMMR in moderately differentiated LUAD tissues. In addition, HMMR has an impact on LUAD patients' overall survival rate [P = 9.5e-06; hazard ratio (HR) = 2]. The level of HMMR expression in LUAD was significantly linked to neutrophils, CD8+T, and CD4+T cells. TMB analysis showed that HMMR could also affect the tumor microenvironment in LUAD. HMMR might be employed as an independent predictive biomarker of LUAD, according to a multivariate COX regression analysis. The findings of GSEA analysis showed that the samples with high HMMR expression levels were rich in cell cycle, cell metabolism, and DNA replication. The analysis results of GSE31210 data are basically consistent with those of TCGA-LUAD.
It is suggested that HMMR has an effect on the occurrence and development of lung adenocarcinoma. Besides, HMMR is also linked to the level of immune infiltration of neutrophils, CD8+T cells, and CD4+T cells and LUAD patients' prognosis. HMMR was suggested to be utilized as a biomarker or therapeutic target to judge the prognosis and immune infiltration of LUAD.
探讨透明质酸介导运动受体（HMMR）在肺腺癌（LUAD）中的表达及其与临床病理特征和肿瘤浸润的关系尚不清楚。
利用癌症细胞系百科全书（CCLE）和癌症基因组图谱（TCGA）-LUAD 检测 HMMR 的表达。采用 TCGA 研究临床病理特征与 HMMR 表达及 LUAD 患者预后的关系。利用肿瘤免疫估计资源（TIMER）数据库分析免疫浸润与 HMMR 的关系。通过基因富集探讨基因集富集分析。利用基因表达综合数据库（GEO）数据和我院数据进行验证。
肺腺癌组织和细胞中 HMMR 的表达水平高于正常组，与临床分期、吸烟史和复发有关，可增加 LUAD 的进展或复发。中分化 LUAD 组织中 HMMR 在病理分级患者中有显著表达。此外，HMMR 对 LUAD 患者的总生存率有影响[P=9.5e-06；风险比（HR）=2]。LUAD 中 HMMR 的表达水平与中性粒细胞、CD8+T 和 CD4+T 细胞显著相关。TMB 分析表明，HMMR 还可以影响 LUAD 的肿瘤微环境。根据多变量 COX 回归分析，HMMR 可能作为 LUAD 的独立预测生物标志物。GSEA 分析结果表明，HMMR 表达水平较高的样本富含细胞周期、细胞代谢和 DNA 复制。GSE31210 数据的分析结果与 TCGA-LUAD 的分析结果基本一致。
提示 HMMR 对肺腺癌的发生发展有影响。此外，HMMR 还与中性粒细胞、CD8+T 细胞和 CD4+T 细胞浸润水平及 LUAD 患者的预后有关。建议将 HMMR 作为判断 LUAD 预后和免疫浸润的标志物或治疗靶点。
